The Capitalist: Lloyds teases wannabe buyers with ‘homebuying tasting menu’ March 12, 2026 Lloyds launches a dining special, private jets welcome puppies on board and City AM takes home gold; catch up on the latest City gossip.
Is the City still sexy? March 12, 2026 The era of the long boozy lunch and male dominated pints down the pub may be over, but relationships matter more than ever in the Square Mile, says Eva sayers Over glasses of red and lunch at The Quality Chop House (not recommended for vegetarians, like myself), a broker who’s been working in the City [...]
Samsung bets on AI tools to win over stressed City workers March 12, 2026 Samsung is pitching its new Galaxy S26 range as a productivity tool for professionals who increasingly rely on one device to manage work, travel and everyday admin. The company has unveiled the S26 series, with UK vice president of product and marketing Annika Bizon describing the launch as a major step forward on hardware and [...]
The Cotswolds Distillery: Defining the brand of English whisky March 12, 2026 Whisky Business: City AM’s monthly look at the world of whisky. There are currently over 60 English Whisky distilleries operating across the country in various stages of evolution. There are 38 currently producing and selling spirit, with the remainder maturing new-make spirit that’s yet to hit the market. When the Cotswolds Distillery started out in 2014, [...]
More Brits eye investing as low-cost platforms elbow into the market March 12, 2026 The UK DIY investment market swelled last year as the rise of low-cost platforms lured more investors into taking the plunge of managing their own assets. The do it yourself market has grown 19 per cent over the past twelve months, totalling £772bn assets under administration, as 18.4m Brits ploughed capital into the market, according [...]
Don’t Panic if you’ve not had time to Study the form March 11, 2026 ONE OF Ireland’s ‘good things’ will be carrying a lot of cash in Friday’s Mares’ Chase (2.40pm). As everything builds towards the Cheltenham Gold Cup later in the day, punters will be piling into Dinoblue, currently 6/4, to make some early gains. Last year’s winner has won three of her four starts since and there [...]
Jonbon can finally make his mark at the Festival March 11, 2026 LAST year those at Cheltenham were treated to one of the best performances in recent Festival memory when Fact To File cruised to victory in the Grade One Ryanair Chase (4.00pm). His ability to jump and travel at pace, plus excess reserves of stamina over this trip, make him ideally suited to this two-and-a-half-mile contest [...]
Haringey peddles two-bike model after Richmond Lime snub March 11, 2026 Haringey has handed Forest and Lime a new four-year dockless e-bike contract, doubling down on a two-operator model just as Richmond moves in the opposite direction and edges towards pushing Lime out. The north London borough’s cabinet this week approved the appointment of two operators for an initial two-year term from 1 April 2026, with [...]
Janus Henderson Group plc Board of Directors Determines by Unanimous Vote that Victory Capital’s Proposal Is Not Superior and Reaffirms Recommendation of Transaction with Trian and General Catalyst March 11, 2026 Special Committee of Board and Its Advisors Reviewed Victory’s Non-Binding Unsolicited Proposal and Determines It Is Not in Best Interests of Janus Henderson and Its Shareholders Reaffirms Recommendation of Take-Private by Trian and General Catalyst Victory’s Proposal Not Actionable; Presents Significant Closing Risk and Uncertain Value
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan March 11, 2026 Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually.